Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MEDI-559 in Healthy Infants
NCT00767416Phase 2Completed
- Sponsor
- MedImmune
- Start
- Oct 2008
- Primary completion
- Dec 2011
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of MEDI-559 in respiratory syncytial virus infection (RSV), sponsored by MedImmune. Started Oct 2008; status: completed.
02
Drugs
MEDI-559
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT00767416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00767416.